Of note, this muscle mass loss is a side effect of rapid weight loss and not necessarily a direct side effect of the medications
This distinction has significant implications for therapeutic strategies
When you take them alongside GLP-1 therapy, they may act as a supportive buffer for your digestive system
What the Evidence Actually Supports Its worth being precise about the state of evidence, because the gap between preclinical research and proven human clinical outcomes is significant in this area: Strong preclinical evidence: Hundreds of cell culture and animal studies demonstrate GHK-Cus biological activity across multiple pathways Moderate clinical evidence for topical applications: Several controlled human trials support skin benefits of topical GHK-Cu formulations Limited human evidence for systemic effects: The more dramatic claims tissue regeneration, gene expression reset, anti-aging effects throughout the body are largely supported by in vitro and animal data without the controlled human trials required to confirm efficacy and safety The scientific communitys interest in GHK-Cu is well-founded
GSH depletion, protein S-glutathionylation and mitochondrial transmembrane potential hyperpolarization are early events in initiation of cell death induced by a mixture of isothiazolinones in HL60 cells
Patients need to understand what each component does, why it was prescribed, and how to manage the different side effect profiles
